Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. Jul 26, 2014; 6(7): 653-662
Published online Jul 26, 2014. doi: 10.4330/wjc.v6.i7.653
Published online Jul 26, 2014. doi: 10.4330/wjc.v6.i7.653
Neuregulin-1/erbB activities with focus on the susceptibility of the heart to anthracyclines
Cecilia Vasti, Cecilia M Hertig, Laboratory of Molecular Cardiology, Institute for Research in Genetic Engineering and Molecular Biology - Dr. Hector N. Torres- (INGEBI), 1428 Buenos Aires, Argentina
Author contributions: Hertig CM planned the structure and was the primary writer of the article; Vasti C contributed to the data collection and prepared figures.
Supported by National Research Council of Argentina, CONICET PIP N° 0722
Correspondence to: Cecilia M Hertig, PhD, INGEBI, Laboratory of Molecular Cardiology, Institute for Research in Genetic Engineering and Molecular Biology - Dr. Hector N. Torres- (INGEBI), Vuelta de Obligado 2490, 1428 Buenos Aires,Argentina. chertig@dna.uba.ar
Telephone: +54-11-47832871 Fax: +54-11-47868578
Received: December 28, 2013
Revised: February 11, 2014
Accepted: May 16, 2014
Published online: July 26, 2014
Processing time: 235 Days and 16.8 Hours
Revised: February 11, 2014
Accepted: May 16, 2014
Published online: July 26, 2014
Processing time: 235 Days and 16.8 Hours
Core Tip
Core tip: We have reviewed the cardiac requirement of neuregulin-1 (NRG1) signaling through the receptor tyrosine kinase erbB2/erbB4. The evidence indicates that the NRG1/erbB signaling pathway displays a panel of activities implicated in maintaining the myocardial architecture during remodeling, which may explain why the combined treatment with antibodies against erbB2 and anthracycline chemotherapy may evolve into a severe dilated cardiomyopathy. We have further examined the potential molecular targets, which have been either inferred from impaired NRG1 signaling or directly assessed by the administration of NRG1. The current working hypotheses have been delineated towards a prospective molecular understanding of NRG1 signaling in heart.